September 14, 2017
Patients with hepatocellular carcinoma who started Nexavar therapy at reduced dosages had a lower total cumulative pill cost and were less likely to discontinue due to adverse effects, according to recently published data. Additionally, lower starting doses did not affect overall survival.
“Prior small retrospective studies have suggested that using a [Nexavar] dosage escalation strategy might be beneficial, or at least not harmful, to patients with HCC,” Kim A. Reiss, MD, from the Perelman Center for Advanced Medicine, Philadelphia, and colleagues wrote. “This retrospective analysis of nearly 5,000 patients with HCC who were prescribed [Nexavar] suggests that starting patients on a reduced starting dose does not reduce OS after propensity score matching for multiple clinical variables.”